Inositol treatment of Alzheimer's Disease: A double blind, cross-over placebo controlled trial

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 20, Issue 4, 1996, Pages 729-735

  Barak, Yoram ^a   Levine, Joseph ^b,c   Glasman, Arie ^a   Elizur, Avner ^a   Belmaker, Robert H ^b  

^a ABARBANEL MENTAL HEALTH CENTER   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c MENTAL HEALTH CENTER   (Israel)

Author keywords

Alzheimer's disease; Inositol

Indexed keywords

INOSITOL; PLACEBO;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LANGUAGE; ORAL DRUG ADMINISTRATION; ORIENTATION;

EID: 0030152979     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/0278-5846(96)00043-7     Document Type: Article

References (14)

1. APPELGATE WB, BLASS JP AND WILLIAMS TF (1990). Instruments for the functional assessment of older patients. NEJM 322: 1207-1214.
2. COYLE JT, PRICE DL AND DELONG MR (1983). Alzheimers disease: a disorder of cortical cholinergic innervation. Science 219: 1184-1190.
3. FISHER SK AND AGRANOFF BW (1987). Receptor activation and inositol lipid hydrolysis in neural tissues. J Neurochem 48: 999-1017.
4. KOFMAN O AND BELMAKER RH (1993). Biochemical, behavioral and clinical studies of the role of inositol in lithium treatment and depression. Biological Psychiatry 34: 839-852.
5. LEVINE J, BARAK Y, GONSALVES M, ELIZUR A, SCHOR H, KOFMAN O, BELMAKER RH (1995). Double blind study of inositol versus placebo in depression. Am J Psychiatry 152: 792-794.
6. LEVINE J, GONZALVES M, BARBAM I, STIER S, ELIZUR A, KOFMAN O, BELMAKER RH (1993a). Inositol 6 gm daily may be effective in depression but not in schizophrenia. Human Psychopharmacology 8: 49-53.
7. LEVINE J, GONSALVES M, BELMAKER RH (1993b). Inositol modulation of second messenger systems: a strategy for psychopharmacology of depression in aging. In: Psychopharmacotherapy in Old Age, M Bergener, RH Belmaker and M Tropper (Eds), pp 254-260. Springer, New York.
8. LEVINE J, RAPAPORT A, LEV L, BERSUDSKY Y, KOFMAN O, BELMAKER RH, SHAPIRO J AND AGAM G (1993c). Inositol treatment raises CSF inositol levels. Brain Research 627: 168-170.
9. McENTEE WJ AND CROOK TH (1991). Serotonin, memory and the ageing brain. Psychopharmacology 103: 143-149.
10. MILLER BL, MOATS RA, SHONK T, ERNST T, WOOLLEY S, ROSS BD (1993). Alzheimer Disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 187: 433-437.
11. MOHS RC, ROSEN WG AND DAVIS KL (1983). The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy. Pharmacol Bull 19: 448-450.
12. ROTH M, TYM E, MOUNTJOY CQ, HUPPERT FA, HENDRIE H, VERMA S, and GODDARD R (1986). CAMDEX, a standardized instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Brit J Psychiatry 149: 698-709.
13. SPITZER RL, WILLIAMS JBW, BIBBON M (1987). Structural clinical interview for DSM III-R -patient verision (SCID-P), New York State Psychiatric Institute, Biometrics Research.
14. TARIOT PN, SUNDERLAND T, WEINGARTNER H, MURPHY DLS, WELKOWITZ JAS, THOMPSON K, COHEN RN (1987). Cognitive effects of L-deprenyl in Alzheimer's disease. Psychopharmacology 91: 489-491.